Vmbook Online ordering
Neuralstem Inc
Neuralstem, Inc is a clinical-stage biopharmaceutical company that focuses on developing and commercializing nervous system disease treatments. The company's stock symbol is CUR, and it is listed on the NASDAQ stock exchange in the US. Here's some general information about Neuralstem, inc., with a focus on its financial performance and growth prospects:
* Neuralstem, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for nervous system diseases.
* The company's lead product candidate is NSI-189, a small molecule that promotes the growth of new neurons and synapses. The company holds Orphan Designation from the FDA for the treatment of amyotrophic lateral sclerosis (ALS) and has completed a Phase 1 clinical trial for that indication.
* The company's pipeline also includes NSI-007, a Phase 2 clinical trial tranquilizer to treat hydrocephalus, a condition in which there is an abnormal accumulation of cerebrospinal fluid in the brain.
* Neuralstem, Inc. has a collaboration agreement with the Biotechnology Center of the Universidad Mayor in Chile to develop novel compounds for treating neurodegenerative diseases.
* The company was founded in 1995 as a University of California, Los Angeles (UCLA) spin-off and has been listed on NASDAQ since 2004.
* The company has received funding from the National Institute of Neurological Disorders and Stroke and the National Cancer Institute, US, as well as from private investors.
* Neuralstem's shares trade under the ticker symbol "CUR" on NASDAQ.
* The company's financial performance is yet to be profitable since its inception, and it has been reporting net losses yearly.
* The company's stock price has been volatile over the past year, ranging from $ 17. 84 in March 2022 to $32.80 in August 2022. The stock's market capitalization is around $1.07 billion as of March 2023.
* Analysts expect the company to continue investing heavily in research and development to advance its product candidates through clinical trials, which may impact its earnings in the near term.
* There is excitement among investors and analysts about the possibility of Neuralstem's technology and pipeline, especially NSI-189, which has shown promise in treating various nervous system diseases.
* Neuralstem faces intense competition from other biotech companies working on similar therapeutic approaches to nervous system diseases.
* The company will need to continue to show positive clinical trial results and progress towards profitability to maintain investor interest and confidence.
In summary, Neuralstem, Inc. is a clinical-stage biotech firm focusing on developing innovative therapies for disorders of the nervous system. Although the company has yet to be profitable, it has a promising product portfolio and ongoing clinical trials. Its lead candidate, NSI-189, has shown encouraging results in treating several central nervous system disorders.